A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans. 27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection.
The safety of transplanting autologous MSCs demonstrated by the clinical trial represents a breakthrough in the potential development of a stem cell based regenerative multiple sclerosis treatment. Principle investigator Antonio Uccelli believes that the results of the clinical trial suggest that the pluripotency of MSCs can be utilized to treat a broad array of diseases, traumas, and injuries.
Mesenchymal stem cells have the unique capacity to differentiate into a multitude of different types of tissues – such as neurons, insulin producing pancreatic beta cells, bone, cartilage, and cardiomyocites amongst them. To learn more about the value of preserving your own MSCs for use in future regenerative therapies and how to bank your own stem cells through a non-invasive and affordable method by recovering your dental pulp stem cells, visit StemSave or call 877-783-6728 (877-StemSave) today.
To view the full article, click here.
To view the clinical trial, click here.
The Future of Regenerative is Now™.